ESR1 and breast cancer: The ability of dieldrin to act as a xenoestrogen has been proposed to underlie its ability to alter mammary carcinogenesis and associated mortality [10], [24], and is based largely on its ability to increase proliferation in estrogen receptor-α (ER-α) positive MCF-7 breast cancer cells [25].